Skip to content
Head to head

AtaiBeckley vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ATAI · VRTX

Updated moments ago

1-year performance, rebased to 100

ATAI +1.8%VRTX +6.1%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals earns the most per share.
ATAIVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price0.00515.02
Change today+0.00%-1.08%
1-year return--+22.0%
Market cap$0$130.58B
52-week range3.27 – 7.45412.27 – 568.67
Valuation
P/E (TTM)0.0033.14
P/E percentile, own 5-yr range58th99th
P/B0.006.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.9115.32
Net profit (TTM)$-1.08B$3.88B
Revenue (TTM)$4.47M$12.95B
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)+137.0%+11.8%
Gross margin--85.5%
Operating margin-3122.6%33.1%
Net margin-14941.7%30.7%
Free cash flow (TTM)$-132.58M$3.20B
Provider cash-flow period date2026-06-292026-09-29
Ownership & sentiment
Institutional ownership54.8%96.8%
Insider activity (12mo)13 buy / 37 sell28 buy / 22 sell
Short interest (% of float)5.2%1.9%
Analyst consensus--95% buy / 5% hold (21)
Analyst price target--$624 (+21%)
StockVane view
StockVane Quant RatingC (0)C (68)
Company
Employees1176,400
Founded--1989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.